White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
Key takeaways
- Lawrence said the White House and Department of Health and Human Services did not respond to multiple inquiries asking if the president was using the obesity drug.
- We shouldn t have to bat down baseless speculation for you to not print it.
- Are you going to now go ask this idiotic question to the ~4 million Americans in this age cohort and then speculate about them being the application? he added.
Why this matters: political developments that affect policy direction and public trust.
The retatrutide drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that approves experimental treatments for patients traditionally suffering from life-threatening illnesses.
Three anonymous sources familiar with the matter told STAT News, the patient approved to receive retatrutide was 79 years old, leading the outlet to believe the prescription could have been issued to Trump who turned 80 last week.
Because this has to be spelled out for @LizzyLaw, who has proven herself to be an unserious gossip columnist, this application was not for the President, White House senior deputy press secretary Kush Desai wrote in a Tuesday post on X, referring to reporter Lizzy Lawrence who authored the article.